Tagged with Strategy,

Mexico Valney Suzuki highlights his focus on expanding access to Novo Nordisk’s innovations in Mexico, especially for vulnerable populations; the importance of ethical usage of the company’s groundbreaking semaglutide-based treatments for diabetes and obesity; and Mexico’s crucial role in Novo Nordisk’s global operations, not just as a market but also in…

China Yoshio Uchida, President of Daiichi Sankyo China, outlines the company’s strategic focus on Antibody-Drug Conjugates (ADCs) within China’s oncology market and China’s relevant role in the company’s global R&D operations. He explains how Daiichi Sankyo is addressing the challenges of a dynamic healthcare environment while emphasizing the company’s commitment to…

China Dr George Chen explores D3 Bio’s strategic approach to drug development, its ambition to launch two cancer therapies in the US within five years, and the critical role of partnerships and funding in achieving these goals. Reflecting on this journey, Dr. Chen emphasizes, “It’s a journey to realize a dream…

Mexico Wiener Lab is a leader in diagnostics, with a strong focus on clinical chemistry, immunology, coagulation, and molecular biology. As Héctor Barillas Soto explains, the company has a significant presence in Mexico and Latin America and specializes in providing advanced diagnostic solutions for both small and large laboratories. Barillas Soto…

China Drawing on a wealth of Big Pharma experience, Jenny Zheng now leads China operations for Illumina, a global leader in genomics, specialising in DNA sequencing technology that drives innovation in healthcare, research, and personalised medicine. Illumina continues to see China as a crucial part of its global strategy due to…

Hong Kong Andrea Chang, general manager of Eisai Hong Kong explains the importance of the firm’s FDA-approved Biogen-partnered Alzheimer’s disease (AD) product, particularly in Hong Kong where some 20 percent of the population is aged 65 or older. In addition, she outlines Eisai’s oncology and neurology-focused portfolio; the potential provided by Hong…

China General manager Guillaume Delmotte explores Ipsen’s strategic initiatives in China, highlighting the importance of innovation, addressing healthcare challenges, and fostering a sustainable, people-centric organization. Delmotte emphasizes the rapid pace of change and the vital role of human connections in driving success.   Moving [our China headquarters] to Shanghai allowed Ipsen…

Hong Kong Tony Cheng, managing director and general manager for Hong Kong & Macau at Merck Healthcare walks us through the challenges and opportunities arising from Hong Kong’s transformation, Merck’s strong local presence, its collaboration with the Hong Kong Science and Technology Park to support local start-ups, the affiliate’s engagement in the…

China After a glittering career in corporate America, in 2011 Jasmine Cui returned to China and in 2015 launched her own biotech, Innocare. The firm, which focuses on oncology and autoimmune disease R&D, has a BTK inhibitor for haematological cancers already approved in China and boasts an extensive pipeline. In conversation…

China Unlike many of its Chinese biotech peers with broad portfolios, Hua Medicine has focused intensively on developing a single product, dorzagliatin, for diabetes. As CEO Li Chen notes, this strategic concentration has allowed Hua Medicine to pioneer in homeostasis control modulation and address specific unmet medical needs in diabetes treatment,…

Saudi Arabia Last year, Dimitri Livadas made the unconventional leap from Big Pharma to a local Saudi firm, Saudi Chemical. In conversation, he explains the motivating factors behind this decision, including Saudi Arabia’s vision for the future, the legacy and growth potential of Saudi Chemical, and the unique opportunity to be part…

Saudi Arabia With over 40 years of history in Saudi Arabia, in 2021 Eli Lilly moved to establish a regional headquarters in the country, underscoring its dedication to the country and region. Now led by Brazilian national Felipe Borges dos Reis, Lilly aims to tackle the pressing health concerns of diabetes and…